Quest Diagnostics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
Quest Diagnostics Incorporated has filed its proxy statement for the 2026 Annual Meeting of Stockholders, detailing director nominations, executive compensation, and auditor ratification.
NYSE
Quest Diagnostics released a supplement to its proxy statement to correct a typographical error regarding the number of outstanding shares.
NYSE
Quest Diagnostics will hold its annual stockholders meeting on May 15, 2025, to vote on director elections, executive compensation, auditor ratification, and a stockholder proposal.
NYSE
Quest Diagnostics has released its notice of the 2025 Annual Meeting of Stockholders, detailing the agenda and providing information on voting procedures.
NYSE
Quest Diagnostics will hold its annual stockholders meeting on May 16, 2024, to vote on director elections, executive compensation, auditor ratification, officer exculpation, and a stockholder proposal on climate risk.
NYSE
Quest Diagnostics is holding its 2024 Annual Meeting of Stockholders to vote on key proposals, including officer exculpation and climate risk management.